Healthpoint
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1971-01-01
- Employees
- 501
- Market Cap
- -
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
Phase 2
Terminated
- Conditions
- Venous Leg Ulcers
- Interventions
- Biological: HP802-247
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 1
- Registration Number
- NCT02154087
Santyl Applications to Diabetic Foot Ulcers
Phase 4
Completed
- Conditions
- Diabetic Foot WoundsDiabetic Foot Ulcers
- Interventions
- Biological: Collagenase SANTYL® OintmentBiological: Hydrogel (if needed) and foam dressing
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 215
- Registration Number
- NCT02111291
Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247
Completed
- Conditions
- Venous Leg Ulcer (VLU)
- Interventions
- Biological: No treatmentBiological: No treatment specified
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 221
- Registration Number
- NCT01970657
Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers
Phase 3
Terminated
- Conditions
- Venous Stasis UlcerUlcerVenous Ulcer
- Interventions
- Other: HP802-247 VehicleBiological: HP802-247
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 252
- Registration Number
- NCT01853384
Study of Oasis Ultra in Diabetic Foot Ulcers
Phase 4
Completed
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Device: OasisOther: Standard
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 82
- Registration Number
- NCT01835379
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
Phase 3
Completed
- Conditions
- Venous Leg Ulcers
- Interventions
- Biological: VehicleBiological: HP802-247
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 155
- Registration Number
- NCT01737762
Long Term Follow Up to Determine the Effects of Collagenase SANTYL Ointment on Scar Formation
Completed
- Conditions
- Follow up to Acute Wound Scar Study
- Interventions
- Biological: Santyl
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 12
- Registration Number
- NCT01705860
Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer
- Conditions
- Venous Leg Ulcer
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 440
- Registration Number
- NCT01658618
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
Phase 3
Completed
- Conditions
- Venous Leg Ulcers
- Interventions
- Biological: VehicleBiological: HP-802-247
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Healthpoint
- Target Recruit Count
- 447
- Registration Number
- NCT01656889
A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa
Phase 2
Withdrawn
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Biological: HP802-247Other: Placebo
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Healthpoint
- Registration Number
- NCT01528306
© Copyright 2025. All Rights Reserved by MedPath